## JKHY: Jack Henry & Associates, Inc. - XLK: Technology

### Executive Summary

No thesis match: MRS_20 2.8% below STRENGTH zone (4.0-10.0%); PEG 2.34 fails VALUE criteria (<1.0); RSI 74 overbought. Stock is in no-man's land without clear edge. Caution: overbought RSI (74).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($173.19)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. This Visa Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday**
- Source: Benzinga | 20251208T130838 | Bullish | Relevance: 99%
-  Several top Wall Street analysts have upgraded their ratings for key companies, including Ulta Beauty, Visa, Jack Henry & Associates, Thermo Fisher Scientific, and Novartis. Notable changes include TD Cowen raising Ulta Beauty's price target to $725 and HSBC boosting Visa's target to $389, reflecting a more bullish outlook across various sectors.

**2. Jack Henry & Associates (JKHY) Upgraded to Outperform with New Price Target**
- Source: GuruFocus | 20251208T123621 | Bullish | Relevance: 98%
-  Keefe, Bruyette & Woods has upgraded Jack Henry & Associates (JKHY) from 'Market Perform' to 'Outperform,' raising the price target from $170 to $215, a 26.47% increase. This upgrade reflects increased optimism for the company, which provides core processing and complementary services for US banks and credit unions. Wall Street analysts forecast an average target price of $185.09 for JKHY, implying a modest upside from its current price.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Keefe, Bruyette | $215 | $170 | +26% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Keefe, Bruyette | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 16 ($0.00M) |
| Sells | 3 ($3.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-0.9%)
- Blackrock Inc.: 8.4% (-2.0%)
- Kayne Anderson Rudni: 6.3% (-2.7%)
- State Street Corpora: 5.7% (+2.4%)
- Morgan Stanley: 3.5% (-52.7%)

### Key Risks

1. Insider selling cluster: $3.5M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.34 elevated, pricing in significant growth expectations. Forward P/E 26.4x stretched relative to 9% growth. Quality metrics strong (ROE 23%, ROA 13%, margin 20%). Balance sheet: low leverage (D/E 0.40). Analyst sentiment positive (1 raises, avg +26%). Insider selling cluster ($3.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.1B |
| Beta | 0.73 |
| 52W Range | $144.12 - $196.00 |
| Short Interest | 6.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.34 |
| Forward P/E | 26.4 |
| Current P/E | 28.7 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 2.8% (minimal 5-day change). Below STRENGTH zone by 1.2pp (needs >4.0% for momentum thesis). MRS_5 (-0.0%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 5.0% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.67), confirming momentum. RSI overbought at 74, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.80% (CS: 76) | Neutral |
| RSI_14 | 74.1 | Overbought |
| MACD Histogram | 0.67 | Bullish |
| vs SMA20 | 1.050x | Above |
| vs SMA50 | 1.123x | Above |
| vs SMA200 | 1.061x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $180.17
- **Stop Loss:** $173.19 (3.9% risk)
- **Target:** $187.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 171
- **Position Value:** $30,809.07
- **Portfolio %:** 30.81%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-03 (Est: $1.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.65 | $1.86 | +12.8% |
| 2025Q2 | $1.50 | $1.56 | +4.1% |
| 2025Q1 | $1.33 | $1.45 | +8.7% |
| 2024Q4 | $1.32 | $1.35 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*